



## Clinical trial results: A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC

### Summary

EudraCT number	2006-004306-50
Trial protocol	IE GB BE CZ DE PT ES NL AT GR IT DK
Global end of trial date	30 June 2010

### Results information

Result version number	v1 (current)
This version publication date	13 April 2016
First version publication date	29 July 2015

### Trial information

#### Trial identification

Sponsor protocol code	A4001050
-----------------------	----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00426660
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 East 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 November 2010
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 June 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the maraviroc expanded access program is to facilitate access to maraviroc for subjects, who have limited therapeutic options and to collect safety data in a larger and more diverse patient population than that which participated in the phase 2/3 clinical trials.

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of study subjects.

Background therapy:

Maraviroc dosage was adjusted according to optimized background therapy (OBT). OBT was selected by the investigator on the basis of local treatment guidelines, treatment history, resistance test results (if available), safety considerations and his/her clinical judgment. OBT was open-label and not provided by the sponsor. Investigational antiretroviral agents available through pre-approval expanded access programs conducted by other pharmaceutical industries sponsors or in Phase 3 or 4 clinical trials or by other means may be appropriate for use as part of background therapy. Subjects experiencing toxicity attributed to drugs in the background regimen were allowed to substitute another antiretroviral agent during the trial. All concomitant antiretroviral agents were recorded on the appropriate CRF.

Evidence for comparator: -

Actual start date of recruitment	21 July 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 6
Country: Number of subjects enrolled	Portugal: 8
Country: Number of subjects enrolled	Spain: 132
Country: Number of subjects enrolled	United Kingdom: 18
Country: Number of subjects enrolled	Austria: 4
Country: Number of subjects enrolled	Belgium: 38
Country: Number of subjects enrolled	France: 193
Country: Number of subjects enrolled	Greece: 11
Country: Number of subjects enrolled	Ireland: 2
Country: Number of subjects enrolled	Italy: 154
Country: Number of subjects enrolled	Australia: 30
Country: Number of subjects enrolled	Canada: 13
Country: Number of subjects enrolled	Chile: 4

Country: Number of subjects enrolled	Argentina: 15
Country: Number of subjects enrolled	Hong Kong: 1
Country: Number of subjects enrolled	India: 28
Country: Number of subjects enrolled	Malaysia: 14
Country: Number of subjects enrolled	Mexico: 22
Country: Number of subjects enrolled	Puerto Rico: 5
Country: Number of subjects enrolled	Romania: 22
Country: Number of subjects enrolled	Switzerland: 5
Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	United States: 293
Country: Number of subjects enrolled	Costa Rica: 13
Worldwide total number of subjects	1032
EEA total number of subjects	588

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	1
Adults (18-64 years)	1008
From 65 to 84 years	23
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Of 2584 subjects screened, 1047 subjects were enrolled in the study. Of these 1047 subjects, 1032 subjects were treated with maraviroc.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Maraviroc
-----------	-----------

Arm description:

Maraviroc 150 milligrams (mg) twice daily (BID), 600 mg BID, or 300 mg BID; dose administered depending on concomitant medications in combination with optimized background therapy (OBT) according to local standard of care.

Arm type	Experimental
Investigational medicinal product name	Maraviroc
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Maraviroc 150 mg twice daily (BID), 600 mg BID, or 300 mg BID; administered orally.

Number of subjects in period 1	Maraviroc
Started	1032
treated	1032
Safety Analysis Set	1032
Completed	916
Not completed	116
Consent withdrawn by subject	18
Adverse Event	23
Death	14
Insufficient Clinical Response	22
Unspecified	23
Protocol Violation	1
Lost to follow-up	15



## Baseline characteristics

### Reporting groups

Reporting group title	Maraviroc
Reporting group description:	
Maraviroc 150 milligrams (mg) twice daily (BID), 600 mg BID, or 300 mg BID; dose administered depending on concomitant medications in combination with optimized background therapy (OBT) according to local standard of care.	

Reporting group values	Maraviroc	Total	
Number of subjects	1032	1032	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	45.6		
standard deviation	± 8.6	-	
Gender categorical			
Units: Subjects			
Female	205	205	
Male	827	827	
Baseline Overall Viral Load: Absolute Value			
Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) at baseline (original scale). Baseline value calculated as average of screening and baseline values if both values were within 1 log <sub>10</sub> difference. Number of subjects contributing to summary statistics at baseline for overall viral load was 979. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: copies/millilitre (mL)			
arithmetic mean	117846.1		
standard deviation	± 321426.5	-	
Baseline Viral Load less than (<) 100,000: Absolute Value			
HIV-1 RNA at baseline (original scale). Baseline value calculated as average of screening and baseline values if both values were within 1 log <sub>10</sub> difference. Number of subjects contributing to summary statistics at baseline for viral load < 100,000 was 729. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: copies/mL			
arithmetic mean	22395.9		
standard deviation	± 25974.4	-	
Baseline Viral Load Greater Than or Equal to (≥) 100,000: Absolute Value			
HIV-1 RNA at baseline (original scale). Baseline value calculated as average of screening and baseline values if both values were within 1 log <sub>10</sub> difference. Number of subjects contributing to summary statistics at baseline for viral load ≥ 100,000 was 250. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: copies/mL			
arithmetic mean	396179		
standard deviation	± 547142.6	-	
Baseline Overall Viral Load: Absolute Value			
HIV-1 RNA at baseline (original scale). Baseline value calculated as average of screening and baseline values if both values were within 1 log <sub>10</sub> difference. Baseline value calculated as average of screening and baseline values if both values were within 1 log <sub>10</sub> difference. Number of subjects contributing to			

summary statistics at baseline for overall viral load was 979. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: copies/mL			
median	25109.5		
full range (min-max)	39 to 5728492	-	
Baseline Viral Load <100,000: Absolute Value			
HIV-1 RNA at baseline (original scale). Baseline value calculated as average of screening and baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistics at baseline for viral load < 100,000 was 729. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: copies/mL			
median	11028.5		
full range (min-max)	39 to 99643	-	
Baseline Viral Load >=100,000: Absolute Value			
HIV-1 RNA at baseline (original scale). Baseline value calculated as average of screening and baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistics at baseline for viral load >= 100,000 was 250. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: copies/mL			
median	234750		
full range (min-max)	100000 to 5728492	-	
Baseline Overall Viral Load: Log Scale			
HIV-1 RNA at baseline (log10 copies/mL). Baseline value calculated as average of screening and baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistic at Baseline was 979. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: log10 copies/mL			
arithmetic mean	4.259		
standard deviation	± 1.0182	-	
Baseline Viral Load <100,000: Log Scale			
HIV-1 RNA at baseline (log10 copies/mL). Baseline value calculated as average of screening and baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistic at Baseline was 729. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: log10 copies/mL			
arithmetic mean	3.859		
standard deviation	± 0.8517	-	
Baseline Viral Load >=100,000: Log Scale			
HIV-1 RNA at baseline (log10 copies/mL). Baseline value calculated as average of screening and baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistic at Baseline was 250. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: log10 copies/mL			
arithmetic mean	5.423		
standard deviation	± 0.3496	-	
Baseline Overall Viral Load: Log Scale			
HIV-1 RNA at baseline (log10 copies/mL). Baseline value calculated as average of screening and baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistic at Baseline was 979. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: log10 copies/mL			
median	4.4		
full range (min-max)	1.591 to 6.758	-	
Baseline Viral Load <100,000: Log Scale			
HIV-1 RNA at baseline (log10 copies/mL). Baseline value calculated as average of screening and			

baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistic at Baseline was 729. Viral loads were not available uniformly for all subjects enrolled in study.

Units: log10 copies/mL			
median	4.043		
full range (min-max)	1.591 to 4.998	-	
Baseline Viral Load $\geq 100,000$ : Log Scale			
HIV-1 RNA at baseline (log10 copies/mL). Baseline value calculated as average of screening and baseline values if both values were within 1 log10 difference. Number of subjects contributing to summary statistic at Baseline was 250. Viral loads were not available uniformly for all subjects enrolled in study.			
Units: log10 copies/mL			
median	5.371		
full range (min-max)	5 to 6.758	-	



## End points

### End points reporting groups

Reporting group title	Maraviroc
Reporting group description: Maraviroc 150 milligrams (mg) twice daily (BID), 600 mg BID, or 300 mg BID; dose administered depending on concomitant medications in combination with optimized background therapy (OBT) according to local standard of care.	

### Primary: Percentage of Subjects With Grade 3 and Grade 4 Adverse Events (AE)

End point title	Percentage of Subjects With Grade 3 and Grade 4 Adverse Events (AE) <sup>[1]</sup>
-----------------	--

End point description:

AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversible or caused imminent danger of death. If same subject had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessment of a reasonable possibility that the investigational product caused or contributed to the AE. Safety analysis set: all subjects who were randomized and received at least one dose of study medication.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
Grade 3 AE: all causality	13.2			
Grade 3 AE: treatment related	2.4			
Grade 4 AE: all causality	6.3			
Grade 4 AE: treatment related	1.6			

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities

End point title	Percentage of Subjects With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities <sup>[2]</sup>
-----------------	---

End point description:

Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3, Severe = events that interrupted subjects usual daily activity and traditionally required systemic drug

therapy or other treatment. Safety analysis set. N = number of subjects evaluable for laboratory abnormalities (with at least one observation of a laboratory test while on study treatment or during lag time); n = number of subjects with at least one observation of given laboratory test while on study treatment or during lag time.

End point type	Primary
End point timeframe:	
Baseline up to Week 144	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1014			
Units: percentage of subjects				
number (not applicable)				
Alanine aminotransferase (ALT) (n=1013)	2.17			
Aspartate aminotransferase (AST) (n=1013)	2.07			
Absolute Neutrophil Count (n=1004)	0.7			
Alkaline Phosphatase (n=1014)	0.39			
Creatinine (n=1014)	0.49			
Gamma-glutamyl transpeptidase (GGT) (n=1014)	4.73			
Hemoglobin (n=1005)	0.2			
Hyperbilirubinemia (n=1013)	1.28			
Hyperuricemia (n=1014)	0.69			
Hypophosphatemia (n=1014)	0.2			
Lipase (n=409)	4.4			
Platelets (n=997)	1.5			
Potassium (hyperkalemia) (n=1014)	0.1			
Serum Amylase (n=1014)	4.83			
Sodium (hyponatremia) (n=1014)	0.1			
Triglycerides (n=1014)	4.73			

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities

End point title	Percentage of Subjects With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities <sup>[3]</sup>
-----------------	---

End point description:

Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 4, Very Severe = events which were unacceptable and intolerable or were irreversible or caused the subjects to be in imminent danger of death. Safety analysis set. N = number of subjects evaluable for laboratory abnormalities (with at least one observation of a laboratory test while on study treatment or during lag time); n = number of subjects with at least one observation of given laboratory test while on study treatment or during lag time.

End point type	Primary
End point timeframe:	
Baseline up to Week 144	
Notes:	
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1014			
Units: percentage of subjects				
number (not applicable)				
ALT (n=1013)	0.79			
AST (n=1013)	0.39			
Absolute Neutrophil Count (n=1004)	0.2			
Alkaline Phosphatase (n=1014)	0			
Creatinine (n=1014)	0.1			
GGT (n=1014)	1.48			
Hemoglobin (n=1005)	0.1			
Hyperbilirubinemia (n=1013)	0.3			
Hyperuricemia (n=1014)	0.1			
Hypophosphatemia (n=1014)	0			
Lipase (n=409)	1.22			
Platelets (n=997)	0.3			
Potassium (hyperkalemia) (n=1014)	0.2			
Serum Amylase (n=1014)	0.3			
Sodium (hyponatremia) (n=1014)	0.2			
Triglycerides (n=1014)	1.97			

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses

End point title	Percentage of Subjects With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses <sup>[4]</sup>
End point description:	
Treatment-emergent AIDS-defining opportunistic illnesses based on investigator classification guided by a predefined list of clinical Category C adverse events per Center for Disease Control (CDC) HIV Classification System. Includes events occurring up to 30 days after last dose of study drug. Safety analysis set.	
End point type	Primary
End point timeframe:	
Baseline up to Week 144	
Notes:	
[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
AIDS encephalopathy	0.1			
Bone tuberculosis	0.1			
Cytomegalovirus infection	0.2			
Extrapulmonary tuberculosis	0.1			
Meningitis cryptococcal	0.1			
Meningitis tuberculous	0.1			
Mycobacterium avium complex infection	0.1			
Mycobacterium kansasii infection	0.1			
Oesophageal candidiasis	0.6			
Pancreatitis bacterial	0.1			
Pneumocystis jiroveci pneumonia	0.1			
Progressive multifocal leukoencephalopathy	0.1			
Pulmonary tuberculosis	0.5			
Toxoplasmosis	0.1			
B-cell lymphoma	0.1			
Hodgkin's disease	0.1			
Kaposi's sarcoma	0.2			
Encephalopathy	0.1			

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral Load

End point title	Percentage of Subjects With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral Load <sup>[5]</sup>
-----------------	--

End point description:

Due to the limited data available for this endpoint, a summary of AIDS related infections by baseline viral load is not clinically meaningful.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[6]</sup>			
Units: percentage of subjects				
number (not applicable)				

Notes:

[6] - Data not analyzed due to the limited data available for this endpoint.

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline/Nadir CD4 Cell Counts

End point title	Percentage of Subjects With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline/Nadir CD4 Cell Counts <sup>[7]</sup>
-----------------	---

End point description:

Due to the limited data available for this endpoint, a summary of AIDS related infections by by Baseline/Nadir CD4 Cell Counts is not clinically meaningful.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[8]</sup>			
Units: percentage of subjects				
number (not applicable)				

Notes:

[8] - Data not analyzed due to the limited data available for this endpoint.

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Time on Therapy

End point title	Percentage of Subjects With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Time on Therapy <sup>[9]</sup>
-----------------	--

End point description:

Due to the limited data available for this endpoint, a summary of AIDS related infections by time is not clinically meaningful.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[10]</sup>			
Units: percentage of subjects				
number (not applicable)				

Notes:

[10] - Data not analyzed due to the limited data available for this endpoint.

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With All Causality Treatment-emergent Adverse (AEs) Events by Gender

End point title	Percentage of Subjects With All Causality Treatment-emergent Adverse (AEs) Events by Gender <sup>[11]</sup>
-----------------	---

End point description:

Treatment-emergent AEs by gender that occurred up to 30 days after the last dose of study medication. Safety analysis set; n = number of subjects evaluable for adverse events.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
Male (n=827)	69.6			
Female (n=205)	73.7			

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Treatment-emergent Adverse Events (AEs) by Race

End point title	Percentage of Subjects With Treatment-emergent Adverse Events (AEs) by Race <sup>[12]</sup>
-----------------	---

End point description:

Treatment-emergent AEs by race that occurred up to 30 days after the last dose of study medication.  
Safety analysis set; n = number of subjects evaluable for adverse events.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
White (n=817)	68.5			
Black (n=106)	67.9			
Asian (n=54)	88.9			
Other Unspecified (n=55)	85.5			

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Treatment-emergent Adverse Events (AEs) by Age

End point title	Percentage of Subjects With Treatment-emergent Adverse Events (AEs) by Age <sup>[13]</sup>
-----------------	--

End point description:

Treatment-emergent AEs by age that occurred up to 30 days after the last dose of study medication.  
Safety analysis set; n = number of subjects evaluable for adverse events.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
<18 years (n=1)	100			
18 to 44 years (n=515)	71.7			
45 to 64 years (n=493)	68.6			
>=65 years (n=23)	82.6			

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology Status

End point title	Percentage of Subjects With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology Status <sup>[14]</sup>
-----------------	--

End point description:

Treatment emergent AEs by hepatitis B and hepatitis C serology status that occurred up to 30 days post last dose. Safety analysis set; n = number of subjects evaluable for adverse events. Abbreviations: HBV = hepatitis B virus, HCV = hepatitis C virus.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to Week 144

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this was an open label, non-randomized, single arm study, only descriptive data was planned to be reported.

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
HBV: negative (n=897)	71.3			
HBV: positive (n=60)	65			
HBV: missing: (n=75)	64			
HCV: negative (n=794)	72.7			
HCV: positive (n=158)	62.7			
HCV: missing (n=80)	63.8			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With $\geq 0.5$ log<sub>10</sub> Reduction From Baseline in Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV 1 RNA)

End point title	Percentage of Subjects With $\geq 0.5$ log <sub>10</sub> Reduction From Baseline in Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV 1 RNA)
-----------------	---

End point description:

Defined as HIV-1 RNA levels < 400 Copies/mL or at least 0.5 Log<sub>10</sub>-decrease from baseline in HIV-1



RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference. Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.

End point type	Secondary
End point timeframe:	
Baseline up to Week 144	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
Day 2-7 (n=26)	46.2			
Week 2 (n=226)	93.8			
Week 4 (n=773)	93			
Week 8 (n=761)	93.2			
Week 12 (n=756)	94			
Week 16 (n=155)	87.7			
Week 20 (n=131)	93.1			
Week 24 (n=557)	91.9			
Week 32 (n=202)	93.1			
Week 40 (n=227)	91.2			
Week 48 (n=228)	89			
Week 60 (n=160)	90			
Week 72 (n=125)	88			
Week 84 (n=79)	84.8			
Week 96 (n=48)	91.7			
Week 108 (n=18)	100			
Week 120 (n=9)	100			
Week 132 (n=4)	100			
Week 144 (n=1)	100			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With $\geq 1.0$ log10 Reduction From Baseline in HIV 1 RNA

End point title	Percentage of Subjects With $\geq 1.0$ log10 Reduction From Baseline in HIV 1 RNA
-----------------	---

End point description:

Defined as HIV-1 RNA levels < 400 copies/mL or at least 1.0 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference. Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.

End point type	Secondary
End point timeframe:	
Baseline up to Week 144	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
Day 2-7 (n=26)	30.8			
Week 2 (n=226)	90.3			
Week 4 (n=773)	90.2			
Week 8 (n=761)	91.2			
Week 12 (n=756)	91.3			
Week 16 (n=155)	82.6			
Week 20 (n=131)	89.3			
Week 24 (n=557)	89			
Week 32 (n=202)	90.1			
Week 40 (n=227)	87.7			
Week 48 (n=228)	86.4			
Week 60 (n=160)	85.6			
Week 72 (n=125)	83.2			
Week 84 (n=79)	79.7			
Week 96 (n=48)	85.4			
Week 108 (n=18)	100			
Week 120 (n=9)	100			
Week 132 (n=4)	100			
Week 144 (n=1)	100			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With HIV-1 RNA Levels Below the Limit of Quantification: <400 Copies/mL

End point title	Percentage of Subjects With HIV-1 RNA Levels Below the Limit of Quantification: <400 Copies/mL
-----------------	--

End point description:

Limit of quantification defined as <400 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference. Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 144

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
Baseline (n=979)	6.7			
Day 2-7 (n=26)	3.8			
Week 2 (n=226)	58.8			
Week 4 (n=773)	72.7			
Week 8 (n=761)	78.8			
Week 12 (n=756)	82.5			
Week 16 (n=155)	75.5			
Week 20 (n=131)	83.2			
Week 24 (n=557)	84.4			
Week 32 (n=202)	83.7			
Week 40 (n=227)	81.1			
Week 48 (n=228)	80.7			
Week 60 (n=160)	78.1			
Week 72 (n=125)	72.8			
Week 84 (n=79)	74.7			
Week 96 (n=48)	75			
Week 108 (n=18)	88.9			
Week 120 (n=9)	77.8			
Week 132 (n=4)	100			
Week 144 (n=1)	100			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With HIV-1 RNA Levels Below the Limit of Quantification: <50 Copies/mL

End point title	Percentage of Subjects With HIV-1 RNA Levels Below the Limit of Quantification: <50 Copies/mL
-----------------	---

End point description:

Limit of quantification defined as <50 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference. Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 144

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of subjects				
number (not applicable)				
Baseline (n=979)	1.7			
Day 2-7 (n=26)	0			
Week 2 (n=226)	19.9			
Week 4 (n=773)	30.1			
Week 8 (n=761)	43.1			
Week 12 (n=756)	45.8			
Week 16 (n=155)	37.4			
Week 20 (n=131)	42.7			
Week 24 (n=557)	55.8			
Week 32 (n=202)	57.4			
Week 40 (n=227)	54.6			
Week 48 (n=228)	54.8			
Week 60 (n=160)	51.9			
Week 72 (n=125)	49.6			
Week 84 (n=79)	55.7			
Week 96 (n=48)	54.2			
Week 108 (n=18)	77.8			
Week 120 (n=9)	44.4			
Week 132 (n=4)	75			
Week 144 (n=1)	100			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in CD4 Cell Count

End point title	Change From Baseline in CD4 Cell Count
End point description:	
Change from baseline in cluster of differentiation 4 helper T cells (CD4) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value. Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.	
End point type	Secondary
End point timeframe:	
Baseline up to Week 144	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: cells per microliter (cells/mcL)				
arithmetic mean (standard deviation)				
Day 2-7 (n=6)	28.5 (± 76.18)			

Week 2 (n=213)	49.7 (± 93.15)			
Week 4 (n=762)	68.9 (± 124.31)			
Week 8 (n=739)	94.5 (± 122.94)			
Week 12 (n=738)	95.7 (± 124.42)			
Week 16 (n=149)	85.9 (± 124.37)			
Week 20 (n=130)	106.6 (± 112.26)			
Week 24 (n=552)	127.8 (± 139.42)			
Week 32 (n=197)	124.1 (± 150.44)			
Week 40 (n=232)	129.2 (± 144.31)			
Week 48 (n=222)	140.5 (± 154.46)			
Week 60 (n=161)	134 (± 151.52)			
Week 72 (n=124)	147 (± 160.92)			
Week 84 (n=72)	141.1 (± 147.55)			
Week 96 (n=50)	160.3 (± 160.78)			
Week 108 (n=19)	242.9 (± 167.06)			
Week 120 (n=8)	117.9 (± 203.49)			
Week 132 (n=4)	179 (± 109.94)			
Week 144 (n=1)	93 (± 0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in CD4 Cell Count Percent

End point title	Change From Baseline in CD4 Cell Count Percent
End point description:	
Change from baseline in CD4 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.	
Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.	
End point type	Secondary
End point timeframe:	
Baseline up to Week 144	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of lymphocytes				
arithmetic mean (standard deviation)				
Days 2-7 (n=6)	-1.3 (± 1.56)			
Week 2 (n=206)	1.8 (± 3.79)			
Week 4 (n=733)	1.6 (± 4.84)			
Week 8 (n=722)	1.4 (± 6.12)			
Week 12 (n=708)	1.6 (± 5.45)			
Week 16 (n=141)	1.9 (± 4.63)			
Week 20 (n=125)	2.2 (± 6.17)			
Week 24 (n=531)	2.8 (± 4.55)			
Week 32 (n=191)	3.2 (± 5.38)			
Week 40 (n=218)	3.7 (± 4.97)			
Week 48 (n=210)	3.5 (± 5.87)			
Week 60 (n=148)	4.5 (± 6.1)			
Week 72 (n=116)	5 (± 6.33)			
Week 84 (n=64)	5.7 (± 6.73)			
Week 96 (n=41)	3.9 (± 6.36)			
Week 108 (n=19)	6.3 (± 6.86)			
Week 120 (n=7)	5.7 (± 9.07)			
Week 132 (n=4)	8.5 (± 8.35)			
Week 144 (n=1)	1 (± 0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in CD8 Cell Count

End point title	Change From Baseline in CD8 Cell Count
End point description:	
Change from baseline in cluster of differentiation 8 suppressor T cells (CD8) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value. Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.	
End point type	Secondary
End point timeframe:	
Baseline up to Week 144	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: cells/mcL				
arithmetic mean (standard deviation)				
Day 2-7 (n=6)	268.5 (± 262.5)			

Week 2 (n=201)	78.2 (± 343.85)			
Week 4 (n=701)	205.6 (± 509.7)			
Week 8 (n=692)	345.6 (± 599.98)			
Week 12 (n=696)	309.4 (± 578.91)			
Week 16 (n=129)	259.6 (± 430.78)			
Week 20 (n=119)	325.2 (± 621.46)			
Week 24 (n=523)	251.3 (± 498.85)			
Week 32 (n=185)	185.2 (± 484.74)			
Week 40 (n=222)	160.9 (± 471.99)			
Week 48 (n=214)	153.2 (± 464.73)			
Week 60 (n=157)	76.9 (± 467.64)			
Week 72 (n=120)	68.7 (± 502.73)			
Week 84 (n=70)	-11.6 (± 548.85)			
Week 96 (n=45)	56.6 (± 403.1)			
Week 108 (n=19)	147.5 (± 600.55)			
Week 120 (n=8)	-135.1 (± 517.02)			
Week 132 (n=4)	-363.3 (± 882.3)			
Week 144 (n=1)	642 (± 0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in CD8 Cell Count Percent

End point title	Change From Baseline in CD8 Cell Count Percent
End point description: Change from baseline in CD8 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value. Safety analysis set; n = number of subjects contributing to summary statistic at given timepoint.	
End point type	Secondary
End point timeframe: Baseline up to Week 144	

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	1032			
Units: percentage of lymphocytes				
arithmetic mean (standard deviation)				
Day 2-7 (n=6)	3 (± 3.42)			
Week 2 (n=197)	-1.5 (± 7.68)			
Week 4 (n=689)	-0.3 (± 8.08)			
Week 8 (n=683)	0.4 (± 9.62)			
Week 12 (n=675)	-0.9 (± 9.95)			
Week 16 (n=125)	0.7 (± 8.66)			
Week 20 (n=115)	-0.7 (± 10.08)			
Week 24 (n=510)	-3.2 (± 8.92)			
Week 32 (n=184)	-4 (± 9.09)			
Week 40 (n=215)	-4.5 (± 8.9)			
Week 48 (n=202)	-5.1 (± 10.63)			
Week 60 (n=146)	-5 (± 11.9)			
Week 72 (n=113)	-6.2 (± 9.87)			
Week 84 (n=64)	-8.2 (± 15.52)			
Week 96 (n=40)	-9.5 (± 10.18)			
Week 108 (n=19)	-14.5 (± 9.99)			
Week 120 (n=6)	-14.5 (± 13.41)			
Week 132 (n=4)	-16.8 (± 12.89)			
Week 144 (n=1)	-2 (± 0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Median Time to Virologic Failure

End point title	Median Time to Virologic Failure
-----------------	----------------------------------

End point description:

Computed as time from the first dose of study medication to the loss of virologic response. Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA  $\geq 0.5$  log<sub>10</sub> copies /mL by the second viral load determination (unless viral load was below the lower limit level of quantification [LLOQ]); or a  $\geq 0.5$  log<sub>10</sub> increase from nadir in HIV 1 RNA after achieving a HIV 1 RNA reduction from BL  $>0.5$  log<sub>10</sub> copies/mL; or a HIV 1 RNA level of  $>1000$  copies/mL after having achieved a HIV 1 RNA level below LLOQ. Safety analysis set. For the calculation of the time to virologic failure, any visits with no data were excluded. Subjects who were not virologic failures were censored at the last available observation.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to Week 144



End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	192 <sup>[15]</sup>			
Units: days				
median (inter-quartile range (Q1-Q3))	86.5 (58 to 169)			

Notes:

[15] - N = number of subjects with virologic failure.

<b>Attachments (see zip file)</b>	Stat Analysis Median Time to Virologic Failure/Statistical
-----------------------------------	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Changes in HIV-1 RNA Level in Subjects Meeting the Definition of Virologic Failure

End point title	Percentage of Subjects With Changes in HIV-1 RNA Level in Subjects Meeting the Definition of Virologic Failure
-----------------	--

End point description:

Reasons for virologic failure: A) failure to achieve a reduction in HIV-1 RNA  $\geq 0.5$  log<sub>10</sub> copies/ml from baseline (BL) by second viral load determination (unless below level of quantification [LOQ]); B)  $\geq 0.5$  log<sub>10</sub> increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from BL  $> 0.5$  log<sub>10</sub> copies/ml ; C) HIV-1 RNA  $> 1000$  copies/ml after having achieved an HIV-1 RNA below LOQ. Safety analysis set.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 144

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	192 <sup>[16]</sup>			
Units: percentage of subjects				
number (not applicable)				
Reduction in HIV-1 RNA $< 0.5$ log <sub>10</sub> copies/ml	43.75			
$\geq 0.5$ log <sub>10</sub> increase from nadir in HIV-1 RNA	31.77			
HIV-1 RNA $> 1000$ copies/ml	18.75			
Reduction $< 0.5$ log <sub>10</sub> + HIV-1 RNA $> 1000$ copies/ml	3.13			
$\geq 0.5$ log <sub>10</sub> increase from nadir + HIV-1 RNA $> 1000$	2.6			

Notes:

[16] - N = number of subjects with virologic failure.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Change in Chemokine Co-receptor Tropism From Screening to Time of Virologic Failure

End point title	Percentage of Subjects With Change in Chemokine Co-receptor Tropism From Screening to Time of Virologic Failure
-----------------	---

End point description:

Tropism status (CCR5 [R5], Dual Mixed [DM], or Non-reportable [NR]) at Screening [Scr] and R5, CXCR4 [X4], DM, or NR) at time of virologic failure (V fail). Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA  $\geq 0.5$  log<sub>10</sub> copies/mL by second viral load determination (unless viral load was below lower limit level of quantification [LLOQ]); or a  $\geq 0.5$  log<sub>10</sub> increase from nadir in HIV 1 RNA after achieving HIV 1 RNA reduction from BL  $> 0.5$  log<sub>10</sub> copies/mL; or a HIV 1 RNA level of  $> 1000$  copies/mL after having achieved a HIV 1 RNA level below LLOQ. Safety analysis set. Abbreviations: Scr = screening, R5 = CCR5 tropic HIV-1, X4=CXCR4 tropic HIV-1, DM = dual mixed, NR = non-reportable, Missing = subjects with VF who did not have tropism result within specified screening period (Scr missing: -42 days to Day 0) or at the time of VF. 1 subject with NR was erroneously enrolled in the study.

End point type	Secondary
----------------	-----------

End point timeframe:

Screening up to Week 144

End point values	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	192 <sup>[17]</sup>			
Units: percentage of subjects				
number (not applicable)				
Scr: Missing; V fail: R5	5.73			
Scr: Missing; V fail: X4	0.52			
Scr: Missing; V fail: DM	1.04			
Scr: Missing; V fail: NR	7.29			
Scr: Missing; V fail: Missing	1.56			
Scr: NR; V fail: R5	0.52			
Scr: R5; V fail: R5	31.25			
Scr: R5; V fail: X4	4.17			
Scr: R5; V fail: DM	18.75			
Scr: R5; V fail: NR	22.92			
Scr: R5; V fail: Missing	6.25			

Notes:

[17] - N = subjects with virologic failure.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)

End point title	Number of Subjects With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)
-----------------	--

End point description:

Virus from subjects who experienced virologic failure was analyzed for resistance to maraviroc. Resistance testing was performed on archived samples of subjects which were available pre-treatment at time of virologic failure. For subjects who met definition of virologic failure during the trial, the sequencing of the V3 loop of HIV-1 viral envelope gp 120 was evaluated to identify any amino acid

changes concomitant with decreased susceptibility to maraviroc. Emergence of resistance was observed least frequently in virus from subjects who failed therapy with maraviroc-susceptible R5 virus, consistent with possibility that they failed because of poor adherence. Here "99999" in results section signifies data not available (NA) due to lack of any distinct mutational pattern for resistance in analyzed subjects.

End point type	Secondary
End point timeframe:	
Baseline up to Week 144	

<b>End point values</b>	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	13 <sup>[18]</sup>			
Units: Subjects	99999			

Notes:

[18] - Data not analysed due to lack of distinct mutational pattern for resistance in analysed subjects.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau

End point title	Number of Subjects With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau
-----------------	---

End point description:

Resistance to maraviroc in viruses from subjects failing therapy with R5 virus was investigated using the in vitro phenotypic (drug susceptibility) assay. The number of subjects who failed with R5 virus were assessed successfully for maraviroc susceptibility at Baseline and Last on-treatment (Week 144). Samples were analyzed for change from Baseline to time of virologic failure in IC 50 and presence of plateau. A maximal percent inhibition (MPI) <95% established as a plateau in inhibition at high concentrations of maraviroc was used to identify viruses which had reduced phenotypic susceptibility to maraviroc.

End point type	Secondary
End point timeframe:	
Baseline up to Week 144	

<b>End point values</b>	Maraviroc			
Subject group type	Reporting group			
Number of subjects analysed	26 <sup>[19]</sup>			
Units: Subjects	14			

Notes:

[19] - N= subjects who were assessed for maraviroc susceptibility

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Treatment emergent adverse events were reported from time of first dose of study drug up to 30 days after last dose of study drug.

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	MARAVIROC
-----------------------	-----------

Reporting group description:

Maraviroc 150 mg twice daily (BID), 600 mg BID, or 300 mg BID; dose administered depending on concomitant medications in combination with optimized background therapy (OBT) according to local standard of care.

Serious adverse events	MARAVIROC		
Total subjects affected by serious adverse events			
subjects affected / exposed	139 / 1032 (13.47%)		
number of deaths (all causes)	16		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anal cancer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
B-cell lymphoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anal squamous cell carcinoma			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Basal cell carcinoma			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hodgkin's disease			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Carcinoma in situ of penis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Penile squamous cell carcinoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Prostate cancer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal cancer			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Gastric cancer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hypertensive crisis			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Orthostatic hypotension			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Coronary artery bypass			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences causally related to treatment / all	1 / 7		
deaths causally related to treatment / all	0 / 0		
Drug interaction			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Chills			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gait disturbance			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hyperthermia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Pyrexia			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences causally related to treatment / all	0 / 12		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Immune system disorders			
Immune reconstitution inflammatory syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cough			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Hypoxia			



subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Lung disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Completed suicide			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Depression			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hallucination, auditory			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Homicidal ideation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Suicidal ideation			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Major depression			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Investigations			
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Blood creatine phosphokinase increased			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Blood glucose increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Clostridium test positive			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatic enzyme increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Weight decreased			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Femur fracture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Joint injury			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Overdose			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post lumbar puncture syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Radius fracture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rib fracture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Toxicity to various agents			

subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Angina unstable			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Left ventricular failure			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Congestive cardiomyopathy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Palpitations			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ventricular tachycardia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Myocardial infarction			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 2		
Nervous system disorders			
Brain oedema			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Convulsion			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Disturbance in attention			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dizziness			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Encephalopathy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Headache			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Paraesthesia			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Syncope</b>			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Presyncope</b>			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Transient ischaemic attack</b>			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
<b>Lymphadenopathy</b>			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Neutropenia</b>			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Thrombocytopenia</b>			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
<b>Ear and labyrinth disorders</b>			

Vertigo			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Vitreous floaters			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Visual impairment			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Vision blurred			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Anogenital dysplasia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anal fissure			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences causally related to treatment / all	1 / 8		
deaths causally related to treatment / all	0 / 0		

Gastritis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Food poisoning				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Inguinal hernia				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mallory-Weiss syndrome				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	3 / 1032 (0.29%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Oesophagitis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rectal polyp				



subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peptic ulcer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Umbilical hernia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	1 / 1		
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatic failure			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatitis			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatitis cholestatic			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatocellular injury			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hypertransaminaemia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hepatotoxicity			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Diabetic foot			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lichenoid keratosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psoriasis			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Stevens-Johnson syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Urinary bladder polyp			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure acute			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Bone pain				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Polyarthritis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Myalgia				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
AIDS dementia complex				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bacteraemia				
subjects affected / exposed	2 / 1032 (0.19%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Bone tuberculosis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bronchitis fungal				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile colitis				

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dermo-hypodermatitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dengue fever			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dysentery			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ear infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Erysipelas			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Extradural abscess			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatitis B			

subjects affected / exposed	2 / 1032 (0.19%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
subjects affected / exposed	3 / 1032 (0.29%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Leptospirosis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection bacterial				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mastoiditis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Meningitis cryptococcal				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mycobacterium avium complex infection				

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mycobacterium kansasii infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis bacterial			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumococcal sepsis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia bacterial			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia legionella			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pulmonary tuberculosis			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pseudomonas infection			

subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory tract infection				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory tract infection bacterial				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sinusitis				
subjects affected / exposed	2 / 1032 (0.19%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Staphylococcal bacteraemia				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				
subjects affected / exposed	4 / 1032 (0.39%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Meningitis tuberculous				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
HIV infection				



subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumonia			
subjects affected / exposed	11 / 1032 (1.07%)		
occurrences causally related to treatment / all	0 / 12		
deaths causally related to treatment / all	0 / 1		
Septic shock			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Sepsis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lactic acidosis			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	MARAVIROC		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	700 / 1032 (67.83%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Basal cell carcinoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Bowen's disease			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Haemangioma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Kaposi's sarcoma			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Lipoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Oral papilloma			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	6		
Prostatic adenoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Penile wart			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Skin papilloma			
subjects affected / exposed	9 / 1032 (0.87%)		
occurrences (all)	11		
Seborrhoeic keratosis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Rectal cancer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Squamous cell carcinoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Squamous cell carcinoma of the tongue			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Thyroid neoplasm			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Testicular neoplasm			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Uterine leiomyoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Vascular disorders			
Aortic stenosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Flushing			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Haematoma			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Haemorrhage			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hot flush			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hypertension			
subjects affected / exposed	22 / 1032 (2.13%)		
occurrences (all)	23		
Hypertensive crisis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Orthostatic hypotension			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Hypotension			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pallor			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Peripheral venous disease			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Phlebitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Thrombophlebitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Venoocclusive disease			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Venous thrombosis			

subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Surgical and medical procedures			
Circumcision			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Papilloma excision			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dental implantation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Prophylaxis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Tooth extraction			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Asthenia			
subjects affected / exposed	22 / 1032 (2.13%)		
occurrences (all)	23		
Chest discomfort			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Chest pain			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	10		
Chills			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Crepitations			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Facial pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Fat tissue increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	24 / 1032 (2.33%)		
occurrences (all)	29		
Feeling hot			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Feeling jittery			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Injection site nodule			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Influenza like illness			
subjects affected / exposed	14 / 1032 (1.36%)		
occurrences (all)	14		
Injection site swelling			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Injection site reaction			
subjects affected / exposed	8 / 1032 (0.78%)		
occurrences (all)	8		
Local swelling			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Malaise			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Mucosal inflammation			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Necrosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Nodule			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Oedema			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Oedema peripheral			
subjects affected / exposed	9 / 1032 (0.87%)		
occurrences (all)	11		
Pain			
subjects affected / exposed	15 / 1032 (1.45%)		
occurrences (all)	15		
Peripheral swelling			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Thirst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	50 / 1032 (4.84%)		
occurrences (all)	56		
Ulcer			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Allergy to arthropod bite			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Food allergy subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Seasonal allergy subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Immune reconstitution inflammatory syndrome subjects affected / exposed occurrences (all)	3 / 1032 (0.29%) 3		
Hypersensitivity subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 3		
Social circumstances Alcohol use subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Amenorrhoea subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Bartholin's cyst subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Breast cyst subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Breast pain subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Cervical polyp			



subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Erectile dysfunction			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	10		
Galactorrhoea			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Genital ulceration			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Genital lesion			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gynaecomastia			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Ovarian cyst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Oedema genital			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Metrorrhagia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pelvic pain			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Prostatism			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Prostatic pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Premenstrual syndrome			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Prostatitis			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	8		
Pruritus genital			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Scrotal ulcer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Retrograde ejaculation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Testicular swelling			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	3		
Testicular pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Uterine cyst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Vulvovaginal discomfort			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Vaginal discharge			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	9		
Asthmatic crisis			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Chronic obstructive pulmonary disease			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Catarrh			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Bronchospasm			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dry throat			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Cyanosis central			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Cough			
subjects affected / exposed	47 / 1032 (4.55%)		
occurrences (all)	61		
Dysphonia			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Dyspnoea			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	12		
Dyspnoea exertional			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Emphysema			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Epistaxis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		

Haemoptysis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hiccups			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Nasal congestion			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Lung disorder			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Oropharyngeal pain			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Interstitial lung disease			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	4		
Pharyngeal erythema			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	6		
Orthopnoea			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pharyngeal ulceration			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Pharyngeal disorder			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Pneumonitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pleurisy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Productive cough			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Respiratory failure			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Respiratory disorder			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Rales			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	12		
Rhinitis allergic			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Sinus congestion			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Respiratory tract congestion			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Tonsillar disorder			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Tonsillar hypertrophy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Sleep apnoea syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Tonsillar ulcer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Psychiatric disorders			
Abnormal dreams			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Aggression			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Agitation			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Anxiety			
subjects affected / exposed	23 / 1032 (2.23%)		
occurrences (all)	24		
Bulimia nervosa			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Bipolar I disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Confusional state			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Depressed mood			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Depression			
subjects affected / exposed	20 / 1032 (1.94%)		
occurrences (all)	21		
Euphoric mood			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dysphoria			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Disorientation			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hallucination			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hallucination, auditory			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Initial insomnia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	32 / 1032 (3.10%)		
occurrences (all)	35		
Libido decreased			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Irritability			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Libido disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Mental disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Mood altered			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Nervousness			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Sleep disorder			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Stereotypy			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Thinking abnormal			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Stress			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Tic			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Withdrawal syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Cholelithiasis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hepatic steatosis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hepatitis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hepatocellular injury			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Hepatitis acute			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hepatomegaly			
subjects affected / exposed	9 / 1032 (0.87%)		
occurrences (all)	9		



Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Hypertransaminasaemia subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Jaundice subjects affected / exposed occurrences (all)	4 / 1032 (0.39%) 4		
Liver disorder subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	13 / 1032 (1.26%) 18		
Amylase increased subjects affected / exposed occurrences (all)	11 / 1032 (1.07%) 15		
Aspartate aminotransferase abnormal subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	9 / 1032 (0.87%) 9		
Blood creatine increased subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Blood cholesterol increased subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Blood alkaline phosphatase subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Blood creatine phosphokinase increased			

subjects affected / exposed	8 / 1032 (0.78%)		
occurrences (all)	8		
Blood creatinine increased			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Blood glucose abnormal			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Blood glucose increased			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Blood iron decreased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Blood phosphorus decreased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Blood pressure increased			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Blood sodium increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Blood triglycerides increased			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	7		
Blood uric acid increased			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Blood urine present			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Cardiac function test abnormal subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Body temperature increased subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Cardiac murmur subjects affected / exposed occurrences (all)	3 / 1032 (0.29%) 3		
Eosinophil count increased subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Carotid bruit subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	12 / 1032 (1.16%) 15		
Glycosylated haemoglobin increased subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Helicobacter test positive subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Haemoglobin decreased subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Hepatic enzyme increased subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Hepatitis B DNA increased subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Hepatitis B antibody positive			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hepatitis B surface antigen positive			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Hepatitis B virus test positive			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Human papilloma virus test positive			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Lipase increased			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Liver function test abnormal			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Low density lipoprotein increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Lymph node palpable			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	3		
Murphy's sign positive			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Occult blood positive			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Prostatic specific antigen increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Platelet count decreased			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Physical examination			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Urine output decreased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Treponema test positive			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Transaminases increased			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Waist circumference increased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	12 / 1032 (1.16%)		
occurrences (all)	13		
Weight increased			
subjects affected / exposed	11 / 1032 (1.07%)		
occurrences (all)	12		
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Ankle fracture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Arthropod bite			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Bone fissure			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Clavicle fracture			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Contusion			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	4		
Fall			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Excoriation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Epicondylitis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Foot fracture			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Foreign body in eye			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Joint injury			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Head injury			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Ligament rupture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Laceration			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Ligament sprain			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Limb injury			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Muscle strain			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Periorbital haematoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Overdose			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Post procedural haematoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Radius fracture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Skeletal injury			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Sunburn			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Thermal burn			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Upper limb fracture			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Congenital, familial and genetic disorders			
Preauricular cyst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dysmorphism			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Accessory spleen			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Cardiac failure congestive			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Cyanosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Extrasystoles			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Left atrial dilatation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hyperdynamic left ventricle			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pericardial effusion			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Palpitations			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Sinus bradycardia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Tachycardia			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		



Nervous system disorders			
Ageusia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Amnesia			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Carpal tunnel syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Ataxia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Aphasia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Central nervous system lesion			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	26 / 1032 (2.52%)		
occurrences (all)	27		
Decreased vibratory sense			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Cerebral atrophy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Epilepsy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dysarthria			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dysaesthesia			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Headache			
subjects affected / exposed	66 / 1032 (6.40%)		
occurrences (all)	70		
Hyperaesthesia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypersomnia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypoaesthesia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Lethargy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Memory impairment			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Loss of consciousness			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Migraine			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Neuralgia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Nerve root compression			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Muscle contractions involuntary			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Neuropathy peripheral			

subjects affected / exposed	14 / 1032 (1.36%)		
occurrences (all)	14		
Paraesthesia			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Radiculopathy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Presyncope			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Sensory disturbance			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Sciatica			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Serotonin syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Sleep phase rhythm disturbance			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Somnolence			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Tension headache			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
VIIth nerve paralysis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Blood and lymphatic system disorders			

Agranulocytosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Anaemia			
subjects affected / exposed	18 / 1032 (1.74%)		
occurrences (all)	19		
Eosinophilia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Bone marrow failure			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Iron deficiency anaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Leukocytosis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Leukopenia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Lymphadenopathy			
subjects affected / exposed	18 / 1032 (1.74%)		
occurrences (all)	19		
Microcytic anaemia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Neutropenia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Microcytosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Polycythaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Splenomegaly subjects affected / exposed occurrences (all)	3 / 1032 (0.29%) 3		
Thrombocytopenia subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Ear and labyrinth disorders			
Tinnitus subjects affected / exposed occurrences (all)	4 / 1032 (0.39%) 4		
Ear pain subjects affected / exposed occurrences (all)	7 / 1032 (0.68%) 8		
Cerumen impaction subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Tympanic membrane hyperaemia subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Vertigo subjects affected / exposed occurrences (all)	12 / 1032 (1.16%) 15		
Eye disorders			
Blepharitis subjects affected / exposed occurrences (all)	3 / 1032 (0.29%) 3		
Blindness unilateral subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Cataract subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Conjunctivitis allergic			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Dry eye			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Exophthalmos			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Eye swelling			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Eye irritation			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Glaucoma			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Foreign body sensation in eyes			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Metamorphopsia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Ocular icterus			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Punctate keratitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pupils unequal			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Uveitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Vision blurred			

subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Visual impairment			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Visual acuity reduced			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Vitreous floaters			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Vitreous detachment			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Abdominal pain			
subjects affected / exposed	20 / 1032 (1.94%)		
occurrences (all)	23		
Abdominal distension			
subjects affected / exposed	16 / 1032 (1.55%)		
occurrences (all)	16		
Abdominal pain lower			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Abdominal pain upper			
subjects affected / exposed	14 / 1032 (1.36%)		
occurrences (all)	19		
Anal fistula			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Abdominal tenderness			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Anal polyp			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Anogenital dysplasia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Anal ulcer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Anorectal discomfort			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Anorectal disorder			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Aphthous stomatitis			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Cheilitis			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Colitis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Colitis ulcerative			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Defaecation urgency			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	35 / 1032 (3.39%)		
occurrences (all)	35		
Dental caries			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		



Diarrhoea haemorrhagic			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	93 / 1032 (9.01%)		
occurrences (all)	109		
Dry mouth			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Dyspepsia			
subjects affected / exposed	13 / 1032 (1.26%)		
occurrences (all)	13		
Dysphagia			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	7		
Eructation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Faecal incontinence			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Faeces soft			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Flatulence			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	10		
Food poisoning			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Functional gastrointestinal disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gastritis			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	10		

Gastric disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gastrointestinal disorder			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Gastrooesophageal reflux disease			
subjects affected / exposed	9 / 1032 (0.87%)		
occurrences (all)	10		
Gastrointestinal pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Glossitis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Haematochezia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Haemorrhoids			
subjects affected / exposed	12 / 1032 (1.16%)		
occurrences (all)	15		
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Haemorrhoids thrombosed			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hyperchlorhydria			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypoaesthesia oral			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Inguinal hernia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Intestinal obstruction			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Irritable bowel syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Large intestine polyp			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Mouth ulceration			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Odynophagia			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Nausea			
subjects affected / exposed	60 / 1032 (5.81%)		
occurrences (all)	67		
Oesophagitis			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Oral discomfort			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Oral disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Oral lichen planus			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Painful defaecation			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	3		
Paraesthesia oral			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Parotid gland enlargement			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Proctalgia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Rectal haemorrhage			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Tongue discolouration			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Salivary gland cyst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Tongue disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Toothache			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Tongue ulceration			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Umbilical hernia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Uvulitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	34 / 1032 (3.29%)		
occurrences (all)	41		
Skin and subcutaneous tissue disorders			
Alopecia			

subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	7		
Actinic keratosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Acne			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Dandruff			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	3		
Dermatitis			
subjects affected / exposed	8 / 1032 (0.78%)		
occurrences (all)	8		
Dermal cyst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Drug eruption			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dermatosis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Dermatitis contact			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Dermatitis acneiform			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Eosinophilic pustular folliculitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Eczema			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	5		
Erythema			

subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Dry skin			
subjects affected / exposed	9 / 1032 (0.87%)		
occurrences (all)	9		
Facial wasting			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hand dermatitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Erythema multiforme			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Lichen planus			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Intertrigo			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Ingrowing nail			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hyperhidrosis			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Lipoatrophy			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Lipohypertrophy			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Lipodystrophy acquired			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Papule			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Onychoclasia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Night sweats			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Nail ridging			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Penile ulceration			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Polymorphic light eruption			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Prurigo			
subjects affected / exposed	8 / 1032 (0.78%)		
occurrences (all)	12		
Psoriasis			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Pruritus			
subjects affected / exposed	22 / 1032 (2.13%)		
occurrences (all)	25		
Purpura			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Rash maculo-papular			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Rash macular			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Rash erythematous			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Rash			
subjects affected / exposed	45 / 1032 (4.36%)		
occurrences (all)	47		
Rash papular			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Rash pruritic			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Rash vesicular			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Seborrhoea			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Seborrhoeic dermatitis			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	7		
Skin exfoliation			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Skin fibrosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Skin fragility			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Skin haemorrhage			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Skin irritation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Skin induration			



subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Skin lesion			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	8		
Skin mass			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	10		
Skin reaction			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Skin ulcer			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Urticaria			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Swelling face			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Renal and urinary disorders			
Bladder disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Calculus bladder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Calculus ureteric			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dysuria			
subjects affected / exposed	9 / 1032 (0.87%)		
occurrences (all)	10		
Chromaturia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Haematuria			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	5		
Microalbuminuria			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Micturition disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Micturition urgency			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Nephritis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Nephroangiosclerosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Nephrolithiasis			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Nephropathy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Polyuria			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Pollakiuria			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	6		
Nocturia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Renal cyst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Renal failure			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Renal impairment			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Renal failure acute			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Ureteral disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Renal pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Urinary hesitation			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Urinary incontinence			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Urinary tract disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Endocrine disorders			
Goitre			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hypogonadism			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypothyroidism			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	34 / 1032 (3.29%)		
occurrences (all)	34		
Arthritis			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	5		
Bone disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	45 / 1032 (4.36%)		
occurrences (all)	51		
Arthropathy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Bone pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Coccydynia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Bursitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Bursa disorder			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Flank pain			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Enthesopathy			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Costochondritis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gouty arthritis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Groin pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypercreatinaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Intervertebral disc protrusion			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Joint stiffness			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Joint range of motion decreased			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Joint swelling			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Muscle atrophy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Limb discomfort			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Muscle contracture			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Muscle spasms			

subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Musculoskeletal chest pain			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Musculoskeletal pain			
subjects affected / exposed	11 / 1032 (1.07%)		
occurrences (all)	11		
Musculoskeletal stiffness			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	20 / 1032 (1.94%)		
occurrences (all)	21		
Neck pain			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Osteitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Osteoarthritis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Osteopenia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Osteonecrosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	20 / 1032 (1.94%)		
occurrences (all)	24		
Polyarthritis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Plantar fasciitis			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Rotator cuff syndrome			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Spinal pain			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Tendon pain			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Synovial cyst			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	2		
Tendonitis			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Tenosynovitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Torticollis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Infections and infestations			
Abscess			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Abscess limb			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Acarodermatitis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Acute hepatitis C			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Anal abscess				
subjects affected / exposed	2 / 1032 (0.19%)			
occurrences (all)	2			
Amoebic dysentery				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences (all)	2			
Acute sinusitis				
subjects affected / exposed	2 / 1032 (0.19%)			
occurrences (all)	2			
Anal fungal infection				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences (all)	1			
Anorectal human papilloma virus infection				
subjects affected / exposed	2 / 1032 (0.19%)			
occurrences (all)	2			
Body tinea				
subjects affected / exposed	2 / 1032 (0.19%)			
occurrences (all)	2			
Bronchiolitis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences (all)	1			
Bronchitis				
subjects affected / exposed	67 / 1032 (6.49%)			
occurrences (all)	79			
Bronchitis bacterial				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences (all)	1			
Campylobacter gastroenteritis				
subjects affected / exposed	1 / 1032 (0.10%)			
occurrences (all)	1			
Candida infection				
subjects affected / exposed	5 / 1032 (0.48%)			
occurrences (all)	5			
Cellulitis				



subjects affected / exposed	8 / 1032 (0.78%)		
occurrences (all)	8		
Chronic hepatitis C			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Chronic sinusitis			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	5		
Conjunctivitis			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	10		
Conjunctivitis viral			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Cytomegalovirus infection			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Diverticulitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Dermo-hypodermatitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Ear infection			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Extrapulmonary tuberculosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Eye infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Fungal infection			

subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Folliculitis			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Fungal skin infection			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Furuncle			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Gastroenteritis viral			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Gastroenteritis			
subjects affected / exposed	17 / 1032 (1.65%)		
occurrences (all)	17		
Gastrointestinal infection			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Gastrointestinal viral infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Genital abscess			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Genital herpes			
subjects affected / exposed	11 / 1032 (1.07%)		
occurrences (all)	13		
Genital herpes simplex			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Genital infection fungal			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Genitourinary chlamydia infection			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gonorrhoea			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gingivitis			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Helicobacter gastritis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Haemophilus infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hepatitis A			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hepatitis B			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Hepatitis C			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Herpes simplex			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	11		
Herpes virus infection			
subjects affected / exposed	10 / 1032 (0.97%)		
occurrences (all)	10		
Herpes zoster			
subjects affected / exposed	18 / 1032 (1.74%)		
occurrences (all)	19		
Hordeolum			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Impetigo			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Infection			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Infected bites			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Infestation			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Laryngitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	29 / 1032 (2.81%)		
occurrences (all)	34		
Localised infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Lower respiratory tract infection			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Mastitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Lymphangitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Mastoiditis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Meningitis aseptic			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Molluscum contagiosum			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Mycotic corneal ulcer			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	39 / 1032 (3.78%)		
occurrences (all)	43		
Oesophageal candidiasis			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	7		
Onychomycosis			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	9		
Oral candidiasis			
subjects affected / exposed	28 / 1032 (2.71%)		
occurrences (all)	41		
Oral fungal infection			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Oral herpes			
subjects affected / exposed	17 / 1032 (1.65%)		
occurrences (all)	18		
Oral hairy leukoplakia			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Oral infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Otitis externa			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Orchitis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Otitis media			

subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	8		
Otitis media acute			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Paronychia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Periodontitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pharyngitis			
subjects affected / exposed	22 / 1032 (2.13%)		
occurrences (all)	25		
Pneumococcal infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	7		
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Prostatitis Escherichia coli			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pulmonary tuberculosis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Purulent discharge			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Pyelonephritis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		

Pyuria			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Rash pustular			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Respiratory tract infection			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	6		
Respiratory tract infection viral			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Rhinitis			
subjects affected / exposed	13 / 1032 (1.26%)		
occurrences (all)	13		
Scrotal infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Secondary syphilis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Sepsis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Shigella infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	28 / 1032 (2.71%)		
occurrences (all)	28		
Skin infection			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Staphylococcal skin infection			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

Staphylococcal infection			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Syphilis			
subjects affected / exposed	7 / 1032 (0.68%)		
occurrences (all)	7		
Tinea infection			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	4		
Tinea cruris			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Tinea pedis			
subjects affected / exposed	5 / 1032 (0.48%)		
occurrences (all)	5		
Tinea versicolour			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Tooth abscess			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	3		
Tooth infection			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Toxoplasmosis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Tracheitis			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	41 / 1032 (3.97%)		
occurrences (all)	62		
Urethritis			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		



Urethritis gonococcal subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Urinary tract infection subjects affected / exposed occurrences (all)	17 / 1032 (1.65%) 19		
Urinary tract infection enterococcal subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Viral infection subjects affected / exposed occurrences (all)	6 / 1032 (0.58%) 7		
Urinary tract infection fungal subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Viral pharyngitis subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Viral sinusitis subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	4 / 1032 (0.39%) 4		
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 1032 (0.19%) 2		
Wound infection subjects affected / exposed occurrences (all)	1 / 1032 (0.10%) 1		
Metabolism and nutrition disorders Cell death			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Decreased appetite			
subjects affected / exposed	9 / 1032 (0.87%)		
occurrences (all)	11		
Dehydration			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Diabetes mellitus			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Dyslipidaemia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hyperamylasaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Gout			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Folate deficiency			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypercalcaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypercholesterolaemia			
subjects affected / exposed	4 / 1032 (0.39%)		
occurrences (all)	4		
Hyperferritinaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hyperglycaemia			
subjects affected / exposed	3 / 1032 (0.29%)		
occurrences (all)	5		
Hyperkalaemia			

subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypertriglyceridaemia			
subjects affected / exposed	25 / 1032 (2.42%)		
occurrences (all)	34		
Hyperlipidaemia			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	7		
Hypocalcaemia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hyperuricaemia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hypocholesterolaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Hypoglycaemia			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hypokalaemia			
subjects affected / exposed	6 / 1032 (0.58%)		
occurrences (all)	6		
Impaired fasting glucose			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Hypovolaemia			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Metabolic syndrome			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Malnutrition			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	3		
Increased appetite			

subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Selenium deficiency			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Type 2 diabetes mellitus			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Vitamin D deficiency			
subjects affected / exposed	2 / 1032 (0.19%)		
occurrences (all)	2		
Vitamin C deficiency			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		
Zinc deficiency			
subjects affected / exposed	1 / 1032 (0.10%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 January 2007	The purpose of this global amendment was to: 1. add a follow up visit 30 days following study drug discontinuation, 2. undertake follow-up of all treatment emergent grade 3 or 4 Adverse Events regardless of causality, until the event resolves or stabilizes at a level acceptable to the investigator. 3. provide information regarding blood sample collection, labelling, storage and study of specified genes for the pharmacogenomics analysis, and 4. include those subjects in a safety registry, who participated in this expanded access program and who continue to receive commercially available maraviroc after study completion.
11 June 2007	This global amendment was added in order to: 1. include smoking assessment and cardiovascular risk assessment to the Schedule of Events, 2. separate the vital signs assessments in the Schedule of Events to specify supine and standing blood pressure for vital signs, 3. move the collection of the pharmacogenomics sample from the Screening visit to the Baseline visit, 4. remove St. John's wort as a contraindicated medication, 5. add criteria for study drug interruption or discontinuation due to laboratory abnormalities, and 6. update the AE reporting period in order that it began from the time of taking the first dose of study drug rather than from time of consent.
29 August 2007	This global amendment was added in order to: 1. add additional Exclusion Criterion to exclude subjects with hypersensitivity to peanut, and 2. include clarification for inclusion of subjects with abnormal laboratory results at the Screening visit.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Viral loads were not available for subjects uniformly as this expanded access study followed local country guidelines and practices that could vary significantly between countries, and testing frequency may have been affected by insurance status.

Notes: